Literature DB >> 24159590

Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.

Kerstin Schütte1, Jan Bornschein, Stefan Kahl, Ricarda Seidensticker, Jörg Arend, Jens Ricke, Peter Malfertheiner.   

Abstract

BACKGROUND: Adherence to surveillance recommendations for patients at risk of developing hepatocellular carcinoma (HCC) is influenced by several factors, including the etiology of chronic liver disease. AIM: The aim of this study was to analyze whether tumor stage at diagnosis and prognosis differ in patients with alcohol-related HCC compared to those with chronic viral hepatitis-related HCC. PATIENTS AND METHODS: Medical records of 650 patients diagnosed with HCC between 1994 and 2011 were analyzed retrospectively. Groups were formed from patients having either alcohol abuse or viral hepatitis (chronic hepatitis B or C virus infection) as the only known HCC risk factors. Demographic data (age and gender), tumor stage at diagnosis, survival, liver function [Child-Pugh-Turcotte (CPT) score] in patients with liver cirrhosis, complications of liver cirrhosis, and serologic parameters were compared between the two groups.
RESULTS: A total of 393 HCC cases (male 84%, median age 65 years) were identified, with alcohol abuse as the causative factor in 76.8% and chronic viral hepatitis in 23.2%. In patients with alcohol abuse, 278 (92.1%) were diagnosed with liver cirrhosis (CPT A 49.3%, CPT B 31.1%, CPT C 9.6%), while in patients with viral hepatitis, 84 (92.3%) suffered from liver cirrhosis (CPT A 59.3%, CPT B 23.1%, CPT C 8.8%). Tumor stage in patients with alcohol abuse was Barcelona Clinic Liver Cancer (BCLC) C in 43.7%, BCLC B in 30.5%, and BCLC A in 14.6%. Patients with viral hepatitis showed a trend toward diagnosis at an earlier tumor stage (BCLC B 35.2%, BCLC C 34.1%, BCLC A 22.2%). Etiology of liver cirrhosis did not significantly influence survival in intermediate and advanced tumor stages, but BCLC-A patients with alcohol-related disease demonstrated prolonged survival compared to patients with viral hepatitis.
CONCLUSION: Tumor stage at diagnosis of HCC is influenced by the etiology of underlying chronic liver disease and is more progressed in patients having a disease with alcoholic etiology. Majority of HCC patients are not diagnosed at a curable stage, which underlines the need for specialized care for all patients with chronic liver disease, independent of etiology and consequent adherence to current surveillance guidelines.

Entities:  

Keywords:  BCLC; HCC; Prognosis; Risk factors; Tumor stage

Year:  2012        PMID: 24159590      PMCID: PMC3760467          DOI: 10.1159/000343840

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  36 in total

1.  Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists.

Authors:  Pratima Sharma; Sameer D Saini; Latoya B Kuhn; Joel H Rubenstein; Darrell S Pardi; Jorge A Marrero; Philip S Schoenfeld
Journal:  Dig Dis Sci       Date:  2010-10-27       Impact factor: 3.199

2.  Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  M Pinter; W Sieghart; F Hucke; I Graziadei; W Vogel; A Maieron; R Königsberg; A Weissmann; G Kornek; J Matejka; R Stauber; R Buder; B Grünberger; M Schöniger-Hekele; C Müller; M Peck-Radosavljevic
Journal:  Aliment Pharmacol Ther       Date:  2011-08-24       Impact factor: 8.171

3.  Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Masashi Fujimori
Journal:  J Vasc Interv Radiol       Date:  2012-01-21       Impact factor: 3.464

4.  Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

Authors:  Florian Hucke; Wolfgang Sieghart; Maximilian Schöniger-Hekele; Markus Peck-Radosavljevic; Christian Müller
Journal:  Wien Klin Wochenschr       Date:  2011-07-29       Impact factor: 1.704

Review 5.  Alcohol and hepatocellular carcinoma.

Authors:  Timothy R Morgan; Sarathy Mandayam; M Mazen Jamal
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress.

Authors:  Helmut K Seitz; Felix Stickel
Journal:  Biol Chem       Date:  2006-04       Impact factor: 3.915

7.  Factors associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers.

Authors:  Eo Rin Cho; Aesun Shin; Kui Son Choi; Hoo-Yeon Lee; Jeongseon Kim
Journal:  Cancer Epidemiol       Date:  2010-10-13       Impact factor: 2.984

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Mayumi Funagayama; Masahiro Kai; Kazuhiro Otani; Jiro Ohuchida
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  12 in total

1.  Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.

Authors:  Charlotte E Costentin; Philippe Sogni; Bruno Falissard; Jean-Claude Barbare; Noelle Bendersky; Olivier Farges; Nathalie Goutte
Journal:  Dig Dis Sci       Date:  2019-07-25       Impact factor: 3.199

Review 2.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

Review 3.  Prevention of Hepatocellular Carcinoma.

Authors:  Kerstin Schütte; Fathi Balbisi; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2016-08-18

Review 4.  Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors.

Authors:  Daniel Q Huang; Philippe Mathurin; Helena Cortez-Pinto; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-10-18       Impact factor: 73.082

5.  Baseline characteristics associated with survival in patients with hepatocellular carcinoma.

Authors:  Seymur Aslanov; Nalan Gulsen Unal; Ali Senkaya; Ferit Celik; Abdullah Murat Buyruk; Alper Uysal; Murat Akyildiz; Ilker Turan; Fulya Gunsar; Galip Ersoz; Abdullah Zeki Karasu; Ahmet Omer Ozutemiz; Ulus Salih Akarca
Journal:  Hepatol Forum       Date:  2021-12-05

6.  Identification of special key genes for alcohol-related hepatocellular carcinoma through bioinformatic analysis.

Authors:  Xiuzhi Zhang; Chunyan Kang; Ningning Li; Xiaoli Liu; Jinzhong Zhang; Fenglan Gao; Liping Dai
Journal:  PeerJ       Date:  2019-02-06       Impact factor: 2.984

Review 7.  Status of, and strategies for improving, adherence to HCC screening and surveillance.

Authors:  Giampiero Francica; Mauro Borzio
Journal:  J Hepatocell Carcinoma       Date:  2019-07-24

8.  APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Lei Cao; Hongwei Cheng; Qiuxia Jiang; Hui Li; Zhixian Wu
Journal:  Aging (Albany NY)       Date:  2020-03-13       Impact factor: 5.682

9.  Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance.

Authors:  Nathalie Ganne-Carrié; Pierre Nahon; Cendrine Chaffaut; Gisèle N'Kontchou; Richard Layese; Etienne Audureau; Sylvie Chevret
Journal:  JHEP Rep       Date:  2021-03-26

10.  Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study.

Authors:  Andrew deLemos; Milin Patel; Samer Gawrieh; Heather Burney; Lara Dakhoul; Ethan Miller; Andrew Scanga; Carla Kettler; Hao Liu; Patrick Roche; Julia Wattacheril; Naga Chalasani
Journal:  Clin Transl Gastroenterol       Date:  2020-03       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.